These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20164668)

  • 1. [Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma].
    Bergmann L
    Onkologie; 2010; 33 Suppl 1():2-4. PubMed ID: 20164668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma].
    Marschner N
    Onkologie; 2010; 33 Suppl 1():12-4. PubMed ID: 20164671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [First-line therapy of metastatic renal cell carcinoma--update 2009].
    Miller K
    Onkologie; 2010; 33 Suppl 1():5-9. PubMed ID: 20164669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monitoring of metastatic renal cell carcinoma--standards and challenges].
    Jäger E
    Onkologie; 2010; 33 Suppl 1():15-7. PubMed ID: 20164672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.
    Hutson TE
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1723-31. PubMed ID: 18928373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
    Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
    J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study of sunitinib malate (SU11248) versus interferon-alpha as first-line treatment in patients with metastatic renal cell carcinoma.
    Reddy K
    Clin Genitourin Cancer; 2006 Jun; 5(1):23-5. PubMed ID: 16859575
    [No Abstract]   [Full Text] [Related]  

  • 10. Sunitinib for the treatment of metastatic renal cell carcinoma.
    Oudard S; Beuselinck B; Decoene J; Albers P
    Cancer Treat Rev; 2011 May; 37(3):178-84. PubMed ID: 20817406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
    Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
    Gschwend JE
    Onkologie; 2010; 33 Suppl 1():10-1. PubMed ID: 20164670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
    Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
    Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Outlook: Future therapy of renal cell carcinoma].
    Bergmann L; Miller K
    Onkologie; 2010; 33 Suppl 1():18-20. PubMed ID: 20164673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
    Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
    Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
    Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
    Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.
    Bellmunt J; Flodgren P; Roigas J; Oudard S
    BJU Int; 2009 Jul; 104(1):10-8. PubMed ID: 19388982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
    Cella D; Bushmakin AG; Cappelleri JC; Charbonneau C; Michaelson MD; Motzer RJ
    Br J Cancer; 2012 Feb; 106(4):646-50. PubMed ID: 22240794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
    Heng DY; Chi KN; Murray N; Jin T; Garcia JA; Bukowski RM; Rini BI; Kollmannsberger C
    Cancer; 2009 Feb; 115(4):776-83. PubMed ID: 19127560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.